JWH-133

JWH-133 is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman.

JWH-133
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H32O
Molar mass312.497 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers . This anti-inflammatory action is induced through agonist action at the CB2 receptor, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids at this receptor completely abolish neurotoxicity related to microglia activation in rat models.

It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid.[1]

As the U.S. Drug Enforcement Administration criminalizes any extract "containing one or more cannabinoids," JWH-133 is a scheduled substance in the U.S.[2] This is despite the low potential for abuse relative to its sister compounds such as JWH-018, as JWH-133 is selective for the non-psychoactive CB2 receptor and thus lacks significant psychoactive effects.

References
  1. Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, Flores JM, García-Real I, Palacios J, Mañes S, Guzmán M, Sánchez C (July 2010). "Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition". Molecular Cancer. 9: 196. doi:10.1186/1476-4598-9-196. PMC 2917429. PMID 20649976. Lay summary – NORML.
  2. "PART 1308 - Section 1308.11 Schedule I". www.deadiversion.usdoj.gov. Retrieved 2020-01-08.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.